Key facts
- This page summarizes Sara Kenkare-Mitra's Form 4 filing for Unicycive Therapeutics, Inc. (UNCY).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Jul 2025, 16:30.
Sara Kenkare-Mitra - 28 Jul 2025 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)
- Reporting relationship
- Director
- Issuer ticker
- UNCY
- Reported as of
- 28 Jul 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Jul 2025, 16:30:14 UTC
- Prior SEC filing
- 01 Jul 2025
- Next SEC filing
- 04 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sara Kenkare-Mitra
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sara Kenkare-Mitra filed Form 4 for Unicycive Therapeutics, Inc. (UNCY) on 30 Jul 2025.
Change
- Previous filing in this sequence was filed on 01 Jul 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001895592
Primary reporting owner
Kenkare-Mitra Sara
- Relationship
- Director
- Address
- C/O UNICYCIVE THERAPEUTICS, INC., 4300 EL CAMINO REAL SUITE 210, LOS ALTOS
- Signature
- /s/ Sara Kenkare-Mitra
- Signature date
- 30 Jul 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
UNCY
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +21,200
- Change %
- +118%
- Price
- $0.000000
- Shares after
- 39,200
- Date
- 28 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,200
- Exercise price
- $4.71
* marks a reported price that did not pass the local price check.